Previous 10 | Next 10 |
2024-05-19 15:05:03 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Biopharma M&A surges year ...
2024-05-16 15:08:23 ET More on MorphoSys MorphoSys: Hold Rating Until The Novartis Deal Closes MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript MorphoSys reports Q1 results New safety risk for MorphoSys drug could complicate Novartis deal - STAT (update) ...
2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...
2024-05-14 06:30:00 ET There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks that investors will want to own. Instead, income-seekers should try to...
2024-05-13 17:41:32 ET More on Voyager Therapeutics Voyager Therapeutics: On Track To Deliver High Returns On Investment Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcr...
2024-05-11 10:00:00 ET More on STOXX Europe 600 Index: Dollar Is Softer Ahead Of The Employment Report Japan Drives Home Message Yen Retreats, While Stronger EMU GDP Underscores Nascent Recovery And Lifts The Euro Five reasons to prefer the European market vs...
2024-05-08 12:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...
2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...
2024-05-05 09:45:00 ET Summary Lantheus Holdings just posted strong Q1 numbers, exceeding expectations and confirming its attractive investment potential. The firm is delivering solid revenue growth, impressive free cash flow, and management raised FY2024 guidance significantly. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...